Thienopyridine therapy influences late outcome after coronary stent implantation

Angiology

Volumn 59, Issue 2, 2008, Pages 172-178

  Aradi, Dániel ^a   Kónyi, Attila ^a   Pálinkás, László ^a   Berki, Tímea ^a   Pintér, Tünde ^a   Tahin, Tamás ^a   Horváth, Iván ^a   Papp, Lajos ^a   Komócsi, András ^a,b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Antiplatelet agents and therapy; Direct stent implantation; Optical aggregometry; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; APYRASE; BIOLOGICAL MARKER; CLOPIDOGREL; COLLAGEN; HEPARIN; PADGEM PROTEIN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ANALYTICAL EQUIPMENT; ANTICOAGULATION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNOFLUORESCENCE TEST; IMPLANTATION; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; STATISTICAL SIGNIFICANCE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOSINE DIPHOSPHATE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RISK FACTORS; STENTS; SURVIVAL ANALYSIS; TICLOPIDINE;

EID: 42049108289     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319707304572     Document Type: Article

References (37)

1. Urban P., Macaya C., Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998 ; 98: 2126-2132.
2. Bertrand ME, Legrand V., Boland J., et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 1998 ; 98: 1597-1603.
3. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study (STARS) investigators. N Engl J Med. 1998 ; 339: 1665-1671.
4. Schomig A., Neumann FJ, Walter H., et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol. 1997 ; 29: 28-34.
5. Schomig A., Neumann FJ, Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996 ; 334: 1084-1089.
6. Bertrand ME, Rupprecht HJ, Urban P., et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000 ; 102: 624-629.
7. Taniuchi M., Kurz HI, Lasala JM Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation. 2001 ; 104: 539-543.
8. Muller C., Buttner HJ, Petersen J., Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation. 2000 ; 101: 590-593.
9. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002 ; 39: 9-14.
10. Bhatt DL Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol. 2004 ; 43: 1127-1129.
11. Gum PA, Kottke-Marchant K., Welsh PA, White J., Topol EJ A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003 ; 41: 961-965.
12. Heptinstall S., Glenn JR, May JA, Storey RF, Wilcox RG Clopidogrel resistance. Catheter Cardiovasc Interv. 2004 ; 63: 397-398.
13. Muller I., Besta F., Schulz C., Massberg S., Schonig A., Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003 ; 89: 783-787.
14. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005 ; 45: 246-251.
15. Berger PB Resistance to antiplatelet drugs: is it real or relevant ? Catheter Cardiovasc Interv. 2004 ; 62: 43-45.
16. Michelson AD Platelet function testing in cardiovascular diseases. Circulation. 2004 ; 110: e489 - e493.
17. Steinhubl SR, Charnigo R., Moliterno DJ Resistance to antiplatelet resistance is it justified ? J Am Coll Cardiol. 2005 ; 45: 1757-1758.
18. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for © 2005 by the American College of Cardiology Foundation and the American Heart Association, Inc. Percutaneous Coronary Intervention). American Heart Association Web Site. http://www.american-heart.org.Updated November 26, 2007.
19. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 2001 ; 37: 2215-2238.
20. Pongracz E. Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke. Clin Hemorheol Microcirc. 2004 ; 30: 237-242.
21. Bernhard D., Csordas A., Henderson B., Rossmann A., Kind M., Wick G. Cigarette smoke metal-catalyzed protein oxidation leads to vascular endothelial cell contraction by depolymerization of microtubules. FASEB J. 2005 ; 19: 1096-1107.
22. Modderman PW Cluster report: CD62. In: Knapp W, Dörken B, Gilks WR, Rieber EP, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989: 1038-1039.
23. Larsen E., Celi A., Gilbert GE, et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989 ; 59: 305-312.
24. Hamburger SA, McEver RP GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood. 1990 ; 75: 550-554.
25. Parmentier S., Kaplan C., Catimel B., McGregor JL New families of adhesion molecules play a vital role in platelet functions. Immunol Today. 1990 ; 11: 225-227.
26. Tan KT, Lip GY The potential role of platelet microparticles in atherosclerosis. Thromb Haemost. 2005 ; 94: 488-492. Review.
27. Eikelboom JW, Hirsh J., Weitz JI, Johnston M., Yi Q., Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002 ; 105: 1650-1655.
28. Antithrombotic Trialists ' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324: 71-86.
29. Patrono C., Bachmann F., Baigent C., et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004 ; 25: 166-181.
30. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004 ; 109: 3171-3175.
31. Miyamoto S., Kawano H., Kudoh T., et al. Usefulness of preprocedural platelet aggregation to predict restenosis after percutaneous coronary intervention. Am J Cardiol. 2005 ; 96: 71-73.
32. Wang K., Zhou X., Zhou Z., Mal N., Fan L., Marc S. Penn. Platelet, Not endothelial, P-selectin is required for neointimal formation after vascular injury. Arterioscler Thromb. Vasc. Biol. 2005 ; 25: 1584-1589.
33. Massberg S., Vogt F., Dickfeld T., Brand K., Page S., Gawaz M. Activated platelets trigger an inflammatory response and enhance migration of aortic smooth muscle cells. Thromb Res. 2003 ; 110: 187-194.
34. Moses JW, Mehran R., Nikolsky E., et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005 ; 45: 1165-1171.
35. Dawkins KD, Grube E., Guagliumi G., et al. TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug eluting stents in contemporary clinical practice. Circulation. 2005 ; 112: 3306-3313.
36. Fajadet J., Morice MC, Bode C., et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005 ; 111: 1040-1044.
37. Fajadet J., Wijns W., Laarman GJ, etal. ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphoryl-choline-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006 ; 114: 798-806.